Background: The true incidence of hidradenitis suppurativa (HS) is unknown.
H idradenitis suppurativa (HS) is a debilitating, painful chronic inflammatory disease whose inherent unpredictability, both with respect to course of disease and response to treatment, poses significant challenges for patients. With sparse epidemiologic data for HS, disease burden has not yet been established. We have previously reported an overall point prevalence of 0.1%, or 98 HS patients per 100,000 people in the United States (US). Group-specific HS prevalence was greatest among women, young adults, and black and biracial patients. 1 There are few adjusted population analyses reporting incidence rates for HS, and the true incidence of HS is unknown. The purpose of this study was to establish standardized 1-and 10-year cumulative incidences for HS in the overall population and in specific demographic groups in the US.
METHODS
We performed a retrospective cohort analysis by querying a multiple health system data analytics and research platform. 2 Clinical information from electronic medical records, laboratories, practice management systems, and claims systems is matched using the single set of Unified Medical Language System ontologies to create longitudinal records for unique patients. The data were standardized and curated according to common controlled vocabularies and classifications systems including International Classification of Diseases, 9th revision (ICD-9), Systemized Nomenclature of MedicinedClinical Terms, Logical Observation Identifiers Names and Codes, RxNorm, and the Diagnostic and Statistical Manual of Mental Disorders, 4th edition. [3] [4] [5] At present, the database encompasses 27 participating integrated health care organizations. More than 48 million unique lives, representing approximately 15% of the population across all 4 census regions of the US, are captured. Patients with all types of insurance and those who are self-pay are represented. The earliest clinical observations in the data system are from 1999. The database is dynamic and performs periodic automatic updates. Population counts are reported by the database to the nearest 10, or represented as \10 if between 0 and 9, to prevent patient identification. In this analysis, all active nondeceased patients in the database at the time of our query (October 2016) were included in this study. The Systemized Nomenclature of MedicinedClinical Terms term ''hidradenitis'' was used to identify incident cases. We randomly reviewed records of 150 patients with an ICD-9 code for HS (705.83) at our institution. Two trained medical students extracted clinical information documented by care providers in each chart. Two dermatologists (A.G. and A.A.) experienced in evaluating HS patients independently reconciled clinical information for each patient against a criterion checklist for the case definition adopted by the 2nd International Conference on Hidradenitis Suppurativa. Cases for which there was disagreement on HS diagnosis were reconciled by discussion between dermatologists. In this cohort, a single ICD-9 code for HS yielded a positive predictive value of 79.3% for diagnosis. This case identification has been shown previously to have a positive predictive value of 77%. 6 
Statistical analysis
We calculated frequencies describing the demographic characteristics of patients with a new diagnosis of HS in the last 1 and 10 years. Sex-and agespecific cumulative incidences were calculated for 4 racial groups: white, African American, biracial (white and African American), and other (all others). Patients with existing HS before the relevant time period were subtracted from the denominator to reflect the true at-risk population. HS incidence over the last 10 years was calculated as an average annual incidence. In order to calculate sex-and agespecific HS incidences for the overall population, the number of new HS cases and total population size were collapsed across the 4 racial groups. Cumulative incidences were standardized using the direct method. The projected year 2000 US population was used as the standard population with 6 age groups: 0-17, 18-29, 30-39, 40-49, 50-59, and $60. 7 Estimates were age-adjusted for sex comparisons, sex-adjusted for age group comparisons, and sex-and age-adjusted for race comparisons. Crude and standardized incidence estimates were calculated based on patients with available race, sex, and age information. Confidence intervals for crude and standardized incidences were computed based on the Poisson distribution and gamma distribution, 8 respectively. Subgroup comparisons were carried out assuming the incidence ratio follows a lognormal distribution. All analyses were performed using SAS software (version 9.4; SAS Institute, Cary, NC).
RESULTS
There were 5410 new diagnoses of HS in the 1-year period beginning in October 2015. Women comprised 73% of new HS diagnoses. New diagnosis was most frequent among patients 18 to 29 years of age (28.6%), followed by patients 30 to 39 years of age (25.2% Table I) .
The 1-year overall incidence for HS was 11.4 (11.1-11.8) per 100,000. One-year group-specific cumulative incidences for HS are listed in Table II . One-year incidence of HS in women was 16.1 (15.5-16.6) per 100,000, more than twice that of men (6.8 Table III ). All 1-year incidence comparisons were significant (P \.0001).
The average annual overall incidence of HS over 10 years was 8.6 (8.6-8.7) per 100,000. Adjusted average annual group-specific cumulative incidences for HS are listed in Table II 
DISCUSSION
In this study, we have described standardized overall and group-specific cumulative incidences for HS over the past 1 and 10 years in the US. Some noteworthy observations for 1-year incidences include an overall incidence of 11.4 per 100,000; an incidence in women more than twice that of men; highest age-group incidence among persons 18 to 29 years of age; incidences that are considerably lower in the pediatric age group and those aged $60 years; and an incidence in African Americans [2.5 times that of whites.
One-year incidences for the overall population and across demographic groups were generally higher than average annual incidences for HS over the past 10 years, which suggests that HS incidence has increased over the past decade. We speculate the increasing incidence may be related to increasing awareness and surveillance of the disease in medical and public sectors and to improving access to care, though a worsening disease epidemic also remains a possibility. Group-specific incidences show similar patterns between the 1-year average annual incidences, with the exception being that average annual incidence among persons 30 to 39 years of age was slightly greater than in persons 18 to 29 years of age. The first and only other study describing population based incidences for HS was completed at the Mayo Clinic. Among their 268 cases having a new diagnosis of HS, they reported the standardized overall average annual incidence rate from 1968 to 2008 in Olmsted County to be 6.0 per 100,000 person-years. Incidence rate was highest in persons 20 to 29 years of age (13.3 per 100,000), followed by persons 30 to 39 years of age (10.5 per 100,000). The highest incidence occurred in women (18.4 per 100,000) and men (7.4 per 100,000) 20 to 29 years of age, followed by women (14.2 per 100,000) and men (6.7 per 100,000) 30 to 39 years of age. In their most recent reporting period (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) , the overall incidence rate was 9.6 per 100,000. Incidence rates for women and men were 14.1 and 5.2 per 100,000, respectively. 9 While ours and the Mayo Clinic study had differing case identification y All comparisons between standardized subgroups were significant (P # .0001). Reference groups for sex, age, and race comparisons were female, 18 to 29 years of age, and white, respectively. z Group-specific results are based on records for which age and sex information was available. As a result, group-specific counts may not add up to totals for all patients in the database.
x Because of the small number of HS cases in the biracial population, age-and sex-specific information was not available, preventing calculation of the standardized incidence. Because of the small number of HS cases in the biracial population, age-specific information was not available. P \ .0001 for all age-specific comparisons with whites as the reference. *Includes Asian, Pacific Islander, Native American, Alaskan Native, Latin American, Native Hawaiian, and unknown.
methods, reported incidences were generally similar. Given the population sample size and heterogeneity in demographic characteristics, our results may be generalized to the US population. In addition, our study reports incidence across race groups, which were not described in the Mayo Clinic study in which [90% of HS patients were white.
There are limitations to our analysis that bear consideration. We could not capture patients with HS who went undiagnosed or those who did not seek care in health systems included in the database, and as such incidence reported herein may be underestimated. Diagnosis of HS could not be chart-verified for the entire dataset because it was deidentified. The extent to which our analysis may have overestimated or underestimated true incidence is not known. It is, however, reassuring that HS incidences reported in this study are similar those in the Olmstead County analysis in which cases were validated.
In conclusion, we report a 1-year cumulative incidence for HS of 11.4 per 100,000 in a well generalized US population. The incidence of HS appears to have increased over the past decade. HS incidence disproportionately impacts women, persons 18 to 29 years of age, and African Americans.
